Abrocitinib showed a favorable safety profile for adult and adolescent patients with moderate to severe atopic dermatitis (AD) in phase 2b and 3 trials.
“We present a pooled analysis from the placebo-controlled phase [2b and 3] studies of the effect of abrocitinib monotherapy on [patient-reported outcome (PRO)] measures in adolescents and adults with moderate to severe AD,” explained the study authors.
Researchers evaluated changes in PRO in 942 patients with moderate to severe AD treated with once-daily oral abrocitinib 200- or 100-mg monotherapy. PRO assessments included global severity, itch, and multi-item measures that assess other signs and symptoms of AD. In addition, depression, anxiety, fatigue, and disease-specific and general health-related quality of life were also included in the assessments.
Improvements were reported from baseline to week 12 across all patient-reported outcomes.
“The results of these analyses suggest that abrocitinib is effective for adult and adolescents with moderate to severe AD,” concluded the study authors. “These results of PRO assessments provide important information on the efficacy of abrocitinib from the patient perspective and complement clinician-reported efficacy and safety outcomes,” they continued. –Lisa Kuhns
Reference
Silverberg JI, Thyssen JP, Simpson EL, et al. Impact of oral abrocitinib monotherapy on patient-reported symptoms and quality of life in adolescents and adults with moderate-to-severe atopic dermatitis: a pooled analysis of patient-reported outcomes. Am J Clin Dermatol. Published May 5, 2021. doi:10.1007/s40257-021-00604-9
